Cytovance Biologics announces Regulatory Strategies for Gene Therapy Product Development webinar
February 08, 2021 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, Okla., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene...
Cytovance Biologics Announces Bin Zhang as Chief Executive Officer
November 09, 2020 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics,...
Cytovance Biologics Announces an Investment in Mass Spectrometry Services
July 15, 2020 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, July 15, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the addition of Mass...
Cytovance Biologics Promotes John Mott to Vice President of Development
July 13, 2020 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, July 13, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the promotion of Dr. John...
Emergent BioSolutions to Invest $75 Million in Canton Site and Expand Viral Vector and Gene Therapy Capability
June 18, 2020 06:30 ET
|
Emergent BioSolutions
Company acquires property adjacent to its Canton, Massachusetts live viral drug substance development and manufacturing facility to increase campus footprint and build out advanced therapy...
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
June 01, 2020 06:30 ET
|
Emergent BioSolutions
Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid domestic production of leading COVID-19 vaccine candidates through 2021...
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
April 23, 2020 18:51 ET
|
Emergent BioSolutions
Emergent will provide contract development and manufacturing services to support Johnson & Johnson’s commitment of one billion doses of vaccine for worldwide emergency pandemic useAgreement valued...
Cytovance Biologics Promotes Dr. Jesse McCool to Chief Executive Officer
March 30, 2020 03:00 ET
|
Cytovance Biologics
OKLAHOMA CITY, March 30, 2020 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO), announces the appointment of Dr. Jesse...
Contract Development and Manufacturing Organization Market worth USD 278.98 Billion by 2026; Increasing Demand for Pharmaceutical Products Will Aid Growth, says Fortune Business Insights™
March 24, 2020 04:08 ET
|
Fortune Business Insights
Pune, March 24, 2020 (GLOBE NEWSWIRE) -- The global contract development and manufacturing organization market size is projected to reach USD 278.98 billion by the end of 2026. Mergers and...
EMERGENT BIOSOLUTIONS SIGNS DEVELOPMENT AND MANUFACTURING AGREEMENT WITH VAXART FOR THEIR EXPERIMENTAL ORAL VACCINE CANDIDATE FOR CORONAVIRUS DISEASE
March 18, 2020 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., March 18, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into an agreement with Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage...